AMENDMENT TO THE SEQUENCE LISTING

Please replace the current paper copy and computer readable form thereof with the attached. No new matter is believed presented.

REMARKS

According to 37 C.F.R. § 1.821(a):

> "amino acid sequences as used in §§ 1.821 through 1.825 are interpreted to mean an unbranced sequence of <u>four or more amino acids</u>..."

(emphasis added).

Upon review of the specification and of prior responses, applicants realize that they have inadvertently labeled sequences which do not satisfy the above rule, and correct this error in this response.

For example, at page 2, paragraph [0019], $Ser^{87}Asn^{88}Gly^{89}Thr^{90}$ clearly constitutes four amino acids, i.e., amino acids 87-90 whereas $Ser^{87}Asn^{88}Thr^{90}Thr^{92}$ and $Ser^{87}Asn^{88}Thr^{90}Ala^{162}$, which were labeled as SEQ ID NOS: 3 and 4 do not. The second series describes a mutation of 3 amino acids in a row, and one that is 71 amino acids away, whereas the first omits amino acid 91, thus disrupting the "rule of four."

Applicants regret any confusion caused by this mistake, and now submit the following corrective amendments. It is believed that no new matter is presented.

Entry of the foregoing amendment is requested.

* * *

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 50-0624, under Order No. NY-ROCHE 202-US (10701185) from which the undersigned is authorized to draw.

Dated: September 17, 2007   Respectfully submitted,

By _____
Norman D. Hanson
Registration No.: 30,946
FULBRIGHT & JAWORSKI L.L.P.
666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)
Attorney for Applicant